| Literature DB >> 25299129 |
Zhifeng Lou1, Haibo Xing2, Da Li3.
Abstract
PURPOSE: In the developed countries, the incidence of esophageal adenocarcinoma (EAC) is increasing over recent decades. The purpose of this meta-analysis was to arrive at quantitative conclusions about the contribution of alcohol intakes and the progression of Barrett's esophagus.Entities:
Mesh:
Year: 2014 PMID: 25299129 PMCID: PMC4191954 DOI: 10.1371/journal.pone.0105612
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow chart of the literature search.
A totaol of 14 observational studies (10 case-control and 4 cohort studies) were indemnified in this meta-analysis.
Characteristics of eligible studies.
| Study; Year | Study design | Site | Age (Year) | Gender (Percent) | Type and No. of cancer | No. of control/non-cancer | Adjustment or matched | Exposure Definition | Quality assessment criteria | |||
| Selection | Selection | Selection | Selection | |||||||||
| Lukić M, et al 2010 | Retrospective Hospital CC | Croatia | 17–83 | NA | EAC 20 | 20 | Age, gender, somking | 4, No, 0.3dL/W,0.5dL/d, >1dL/d | ** | * | *** | 6 |
| Anandasabapathy S, et al 2007 | Retrospective Hospital CC | USA | 25–85 | M 76.15 | HGD/EAC 35 | 74 | Sex, men, hiatal hernia size, Barrett length, GERD symptom, GERD duration, H. pylori absent, race, smoking | 2, 1–6 drinks/wk, 7 drinks/wk | ** | ** | *** | 7 |
| Bani-Hani KE, et al 2005 | Retrospective Hospital CC | China | 2–94 | M 56 | EAC 44 | 553 | Age ≥60 yr, male sex, NSAIDs, EAC, stricture | 2, Non-alcohol use, regular alcohol use | *** | ** | *** | 8 |
| Coleman HG, et al 2012 | Retrospective Population Cohort | UK | 62 | M 62.80 | HGD/EAC 117 | 3050 | Age groups, sex, presence of low-grade dysplasia, income deprivation quintile, Barrett segment length and presence of reflux symptoms. | 3, None, 10 units/week, 10 units/week | *** | ** | *** | 8 |
| Anderson LA, et al 2007 | Retrospective PopulationCC | UK | 63.4 | M 82.86 | EAC 227 | 224 | Age, gender | 2, Never, ever | ** | ** | ** | 6 |
| de Jonge PJ, et al 2006 | Prospective Hospital CC | Netherlands | 62.5 | M 76 | EAC 91 | 244 | Age, gender, educational level, smoking, and reflux symptoms | 3, Never, former, current | *** | ** | *** | 8 |
| Gatenby PA, et al 2008 | Retrospective Hospital Cohort | UK | 63.4 | M 62.5 | HGD/AC 63 | 1002 | Age, gender | 2, High, low | *** | * | ** | 6 |
| Achkar JP, et al 1995 | Retrospective Hospital CC | USA | 63.5 | M 96.47 | EAC 85 | 85 | Age, sex, tobacco smoking | 2, Alcohol abuse, non alcohol abuse | ** | ** | ** | 6 |
| Sikkema M, et al 2011 | Prospective Population CC | Netherlands | 20–86 | M 74 | HGD/EAC 26 | 687 | Age and gender | 3, Never,former,current | *** | ** | *** | 8 |
| Jung KW, et al 2011 | Retrospective Population Cohort | USA | 61.94 | M 69.61 | HGD/EAC 26 | 329 | Age | 3, None, current, past | ** | * | ** | 5 |
| Casson AG, et al 2005 | Prospective Hospital CC | Canada | NA | M 77.35 | EAC 56 | 125 | Age, gender, smoking | 2, Ever, never | * | * | ** | 4 |
| Gray MR, et al 1993 | Retrospective Hospital CC | UK | 31–83 | M 83.95 | EA 23 | 58 | Age, sex | 2, Ever, never | ** | ** | ** | 6 |
| Olliver JR, et al 2005 | Prospective Hospital CC | UK | 30–86 | M 72.97 | EA 24 | 50 | Age, sex | 2, Ever, never | ** | * | ** | 5 |
| Hardikar S, et al 2013 | Prospective Population Cohort | USA | 61.2 | M 81.3 | EA 45 | 366 | Age, gender, WHR, NSAID use and cigarette smoking | 4,0, 0–1, 1–3, >3 drinks/day | *** | ** | ** | 7 |
NA: not available; CC: case-control study; LGD: low-grade dysplasia; EAC: esophageal adenocarcinoma; NASID: non-steroids antiinflammatory drugs; GERD: gastroesophageal reflux disease; WHR: waist-to-hip ratio; BMI: bady mass index; BE: Barrett esophagus; M: male.
The study quality was assessed by Newcastle-Ottawa Scale.
Figure 2Forest plot of the association between alcohol drinking and risk of Barrett's esophagus progressiom.
Subgroup analysis of alcohol consumption and BE progression with combined RR.
| Subgroups | No. of studies | Summary Effect | Study Heterogeneity | ||||
| RR | 95% CI | P Value | I2, % | P Value | |||
| Study design | Cohort | 4 | 0.97 | 0.67 to 1.42 | 0.887 | 0.00% | 0.554 |
| Case-control | 10 | 1.2 | 0.96 to 1.51 | 0.115 | 50.80% | 0.026 | |
| Population-based | 6 | 0.99 | 0.87 to 1.13 | 0.932 | 38.80% | 0.0862 | |
| Hospital-based | 9 | 1.267 | 0.92 to 1.75 | 0.110 | 0.00% | 0.932 | |
| Prospective | 6 | 0.980 | 0.86 to 1.12 | 0.767 | 0 | 0.776 | |
| Retrospective | 8 | 1.31 | 0.98 to 1.75 | 0.064 | 30.30% | 0.186 | |
| Design | High vs low | 6 | 1.002 | 0.85 to 1.18 | 0.978 | 0.00% | 0.794 |
| Ever vs never | 9 | 1.252 | 0.91 to 1.73 | 0.175 | 67.30% | 0.001 | |
| End | HGD and EAC | 5 | 1.017 | 0.72 to 1.45 | 0.926 | 0.00% | 0.658 |
| EAC | 11 | 1.129 | 0.91 to 1.40 | 0.272 | 49.90% | 0.025 | |
| Site | Europe | 8 | 1.00 | 0.88 to 1.13 | 0.938 | 0 | 0.494 |
| Americas | 5 | 1.656 | 1.27 to 2.15 | <0.001 | 0 | 0.484 | |
| Asia | 1 | 1.142 | 0.95 to 1.38 | 0.766 | - | - | |
HGD: high-grade dysplasia; EAC: esophageal adenocarcinoma; RR, relative risk; CI, confidence interval.